Resources

Why do some patients see impressive results with GLP-1 therapies while others barely respond? This question is becoming more relevant as clinicians encounter variability in outcomes. GLP-1 resistance is emerging as a possible explanation for suboptimal responses in certain individuals with diabetes. As a result, understanding how to identify and …

The rise of oral GLP-1 medications is changing how clinicians approach type 2 diabetes treatment. But what if one of the biggest barriers, strict dosing requirements, suddenly disappeared? A newly approved oral option without food or water restrictions is making that question very real. As a result, clinicians now have …

Can we actually prevent type 1 diabetes before symptoms appear? Increasingly, the answer is yes. As research evolves, clinicians now have stronger tools to identify at-risk children earlier and delay disease progression. This shift is especially important because type 1 diabetes often develops silently before diagnosis. Therefore, early screening and …

When managing diabetes, most people focus on A1C or time in range. However, what if the real opportunity lies in something more immediate and actionable? Managing post-meal blood sugar, often called postprandial glucose control, may hold the key to better outcomes. While long-term markers still matter, post-meal spikes often go …

Diabetic ketoacidosis remains one of the most serious complications of diabetes, yet managing it often relies on intermittent data points. What if clinicians could see ketone levels change in real time instead of waiting hours between lab tests? Continuous ketone monitoring for DKA is now emerging as a promising concept …

Patients today are more informed than ever, but are they always getting the full picture? With headlines and social media amplifying new findings, counseling patients on GLP-1 therapies has become more complex. Many individuals now ask about benefits beyond glucose control and weight loss, from heart protection to cognitive health. …

Can a therapy improve metabolic health even if the scale does not budge? This question is becoming increasingly relevant as clinicians observe patients benefiting from GLP-1 therapy even without significant weight loss. While weight reduction has long been a primary goal of incretin-based therapies, emerging data suggest that metabolic improvements …

Could taking a pill instead of an injection change how early people begin treatment for type 2 diabetes or obesity? In 2026, these oral GLP-1 medications are gaining attention for their simplified dosing and improved convenience. As newer formulations reduce traditional barriers, clinicians are beginning to rethink when to initiate …

Can a chronic condition like type 1 diabetes be slowed before it fully develops? Recent long-term studies suggest that preventing or delaying type 1 diabetes may be closer to reality than once believed. In fact, emerging immunotherapy data is changing how clinicians view early-stage disease and the opportunity to intervene …

Managing hyperglycemia in oncology patients is becoming a critical part of cancer care, especially as newer therapies affect glucose metabolism. Have you ever wondered why patients with no history of diabetes suddenly develop high blood sugar during treatment? This growing challenge highlights the need for structured, practical approaches. In this …